Try our beta test site
3 studies found for:    Open Studies | Waldenström’s Macroglobulinemia | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: Dexamethasone, Rituximab, Cyclophosphamide;   Drug: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
2 Recruiting A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: BGB-3111;   Drug: Ibrutinib
3 Recruiting Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Conditions: Chronic Lymphocytic Leukemia;   Indolent B-cell Lymphomas;   Chronic Hepatitis B;   Lymphoma, Small Lymphocytic;   Mantle-Cell Lymphoma;   Waldenstrom's Macroglobulinaemia;   Follicular Lymphoma
Intervention: Drug: Ibrutinib

Study has passed its completion date and status has not been verified in more than two years.